Curaleaf, a marijuana company valued at $4 billion, and Penn Medicine have big plans for Pennsylvania, specifically in King of Prussia, writes Sam Wood for the Philadelphia Inquirer.

Both a grower and retailer, Curaleaf currently operates in 10 states with permits pending in California and Pennsylvania.

The company plans to open six dispensaries in Pennsylvania and an indoor growing facility in King of Prussia. Curaleaf has partnered with an undisclosed academic clinical research center that is thought to be the University of Pennsylvania School of Medicine.

Curaleaf management has ties to Penn through senior vice president of marketing, Katrina Yolen, and senior vice president of business development, Eduard Kelenchuk, with both having MBAs from Penn’s Wharton School of Business. Meanwhile, board director Karl Johansson earned his law degree from Penn.

However, a formal partnership between them still needs the approval of the Pennsylvania Department of Health.

Read more about Curaleaf and Penn Medicine in the Philadelphia Inquirer here.